https://www.live-feeds.com/feed/why-abbvie-is-spending-11-billion-to-buy-apogee-therapeutics-and-why-the-stock-is-risingContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/why-abbvie-is-spending-11-billion-to-buy-apogee-therapeutics-and-why-the-stock-is-risinghttps://www.live-feeds.com/feed/why-abbvie-is-spending-11-billion-to-buy-apogee-therapeutics-and-why-the-stock-is-rising#u15204Sat, 27 Jun 2026 03:27:19 +0000AbbVie has agreed to buy Waltham-based biotech Apogee Therapeutics in a cash transaction. The deal aims to expand AbbVie's immunology portfolio with long-acting drug candidates. This represents the company's largest buyout in over five years.What's confirmed:AbbVie is acquiring Apogee Therapeutics for $10.9 billion.The acquisition is a cash deal.The deal focuses on Apogee's long-acting immunology and inflammation drug candidates.This is the largest buyout AbbVie has made in more than five years.Apogee is based in Waltham.Still unconfirmed:The acquisition price represents a 49% p